Insider Selling: Surgery Partners (NASDAQ:SGRY) Insider Sells 8,785 Shares of Stock

Surgery Partners, Inc. (NASDAQ:SGRY) insider Marissa Brittenham sold 8,785 shares of Surgery Partners stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $13.70, for a total transaction of $120,354.50. Following the completion of the sale, the insider directly owned 54,623 shares of the company’s stock, valued at approximately $748,335.10. This trade represents a 13.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Surgery Partners Stock Performance

Shares of NASDAQ SGRY traded down $0.06 during midday trading on Monday, hitting $13.30. 1,453,571 shares of the stock traded hands, compared to its average volume of 1,733,344. The firm has a market capitalization of $1.72 billion, a P/E ratio of -21.45 and a beta of 1.95. Surgery Partners, Inc. has a one year low of $12.25 and a one year high of $24.60. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87. The firm has a 50-day moving average of $15.16 and a two-hundred day moving average of $18.00.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The firm had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The firm’s revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.44 EPS. On average, equities analysts forecast that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Surgery Partners declared that its Board of Directors has authorized a stock buyback program on Thursday, February 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 9.7% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.

Surgery Partners News Summary

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

Institutional Investors Weigh In On Surgery Partners

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its position in shares of Surgery Partners by 3.8% in the fourth quarter. Janus Henderson Group PLC now owns 13,537,984 shares of the company’s stock valued at $209,162,000 after acquiring an additional 501,401 shares in the last quarter. Pentwater Capital Management LP grew its position in shares of Surgery Partners by 66.9% during the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock worth $252,777,000 after purchasing an additional 4,681,000 shares in the last quarter. UBS Group AG raised its stake in Surgery Partners by 111.4% during the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock valued at $120,571,000 after purchasing an additional 4,113,052 shares during the period. Vanguard Group Inc. raised its stake in Surgery Partners by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 7,614,514 shares of the company’s stock valued at $164,778,000 after purchasing an additional 424,518 shares during the period. Finally, King Street Capital Management L.P. lifted its holdings in Surgery Partners by 24.5% in the 2nd quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock worth $138,382,000 after purchasing an additional 1,225,000 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. UBS Group decreased their price target on shares of Surgery Partners from $29.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday. Jefferies Financial Group reiterated a “buy” rating on shares of Surgery Partners in a research report on Wednesday, March 4th. Barclays cut their price target on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. Finally, Benchmark reiterated a “buy” rating on shares of Surgery Partners in a research note on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.45.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.